These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38617106)

  • 1. The Forgotten Virus, Hepatitis D: A Review of Epidemiology, Diagnosis, and Current Treatment Strategies.
    Khattak A; Vongsavath T; Haque L; Narwan A; Gish RG
    J Clin Exp Hepatol; 2024; 14(5):101395. PubMed ID: 38617106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy.
    Soriano V; Moreno-Torres V; Treviño A; Corral O; de Mendoza C
    Drug Des Devel Ther; 2023; 17():155-166. PubMed ID: 36712949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect].
    Nkongolo S; Hollnberger J; Urban S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Feb; 65(2):254-263. PubMed ID: 35028672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis D: A Review.
    Negro F; Lok AS
    JAMA; 2023 Dec; 330(24):2376-2387. PubMed ID: 37943548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort.
    de Lédinghen V; Fougerou-Leurent C; Le Pabic E; Pol S; Alfaiate D; Lacombe K; Hilleret MN; Lascoux-Combe C; Minello A; Billaud E; Rosa I; Gervais A; Ratziu V; Ganne N; Pageaux GP; Leroy V; Loustaud-Ratti V; Mathurin P; Chas J; Jezequel C; Métivier S; Dumortier J; Arpurt JP; Asselah T; Roche B; Le Gruyer A; Valantin MA; Scholtès C; Gordien E; Tual C; Kortebi A; Coulibaly F; Rosenthal E; Subic-Levrero M; Roulot D; Zoulim F;
    JHEP Rep; 2024 Aug; 6(8):101057. PubMed ID: 39045338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life.
    Asselah T; Loureiro D; Le Gal F; Narguet S; Brichler S; Bouton V; Abazid M; Boyer N; Giuly N; Gerber A; Tout I; Maylin S; Bed CM; Marcellin P; Castelnau C; Gordien E; Mansouri A
    Liver Int; 2021 Jul; 41(7):1509-1517. PubMed ID: 33999515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapies for hepatitis delta virus infection.
    Loureiro D; Castelnau C; Tout I; Boyer N; Narguet S; Menasria Benazzouz S; Louis Z; Pons-Kerjean N; Giuly N; Marcellin P; Mansouri A; Asselah T
    Liver Int; 2021 Jun; 41 Suppl 1():30-37. PubMed ID: 34155804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis D virus: Improving virological knowledge to develop new treatments.
    Khalfi P; Kennedy PT; Majzoub K; Asselah T
    Antiviral Res; 2023 Jan; 209():105461. PubMed ID: 36396025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the Path Forward to Treat Hepatitis Delta Virus?: Old Treatments and New Options.
    Asselah T
    Clin Liver Dis; 2023 Nov; 27(4):985-995. PubMed ID: 37778781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future treatments for hepatitis delta virus infection.
    Asselah T; Loureiro D; Tout I; Castelnau C; Boyer N; Marcellin P; Mansouri A
    Liver Int; 2020 Feb; 40 Suppl 1():54-60. PubMed ID: 32077603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bulevirtide and emerging drugs for the treatment of hepatitis D.
    Xu HY; Yang JO; Chen PH; Han SB
    Expert Opin Biol Ther; 2023; 23(12):1245-1253. PubMed ID: 37853604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
    Yurdaydin C; Keskin O; Kalkan Ç; Karakaya F; Çalişkan A; Karatayli E; Karatayli S; Bozdayi AM; Koh C; Heller T; Idilman R; Glenn JS
    Hepatology; 2018 Apr; 67(4):1224-1236. PubMed ID: 29152762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging anti-HDV drugs and HBV cure strategies with anti-HDV activity.
    Roca Suarez AA; Batbold E; Bartosch B; Dashdorj N; Testoni B; Zoulim F
    Liver Int; 2023 Aug; 43 Suppl 1():87-95. PubMed ID: 37017060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.
    Jachs M; Schwarz C; Panzer M; Binter T; Aberle SW; Hartl L; Dax K; Aigner E; Stättermayer AF; Munda P; Graziadei I; Holzmann H; Trauner M; Zoller H; Gschwantler M; Mandorfer M; Reiberger T; Ferenci P
    Aliment Pharmacol Ther; 2022 Jul; 56(1):144-154. PubMed ID: 35514008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
    Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; Scholtes C; Holzmann H; van Bömmel F; Borghi M; Perbellini R; Rimondi A; Farina E; Trombetta E; Manunta M; Porretti L; Prati D; Ceriotti F; Zoulim F; Bertoletti A; Lampertico P
    J Hepatol; 2022 Feb; 76(2):464-469. PubMed ID: 34699951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial.
    Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Berger A; Ciesek S; Manuilov D; Mercier RC; Da BL; Chee GM; Li M; Flaherty JF; Lau AH; Osinusi A; Schulze Zur Wiesch J; Cornberg M; Zeuzem S; Lampertico P
    J Hepatol; 2024 May; ():. PubMed ID: 38734383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.
    Degasperi E; Anolli MP; Uceda Renteria SC; Sambarino D; Borghi M; Perbellini R; Scholtes C; Facchetti F; Loglio A; Monico S; Fraquelli M; Costantino A; Ceriotti F; Zoulim F; Lampertico P
    J Hepatol; 2022 Dec; 77(6):1525-1531. PubMed ID: 35973578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bulevirtide for patients with compensated chronic hepatitis delta: A review.
    Degasperi E; Anolli MP; Lampertico P
    Liver Int; 2023 Aug; 43 Suppl 1():80-86. PubMed ID: 35942695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
    Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
    Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.